Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced in late July-September 2014.

reinnervate Ltd. is commercializing Alvetex, a three-dimensional scaffold for cell culture. By supporting cell cultures that are more representative of the original tissues, Alvetex cultures could help drug companies fail drugs at an earlier stage, and could reduce the numbers of animals required in testing, thereby saving money in drug development.

The stem cell market is beginning to show signs of significant revenue growth ahead, a development fueled by research in a variety of disease categories, some of which has already produced accepted therapies. In February, about three dozen firms gathered at the 5th Annual Stem Cell Summit, where participants showcased their technology in the hopes of securing financing.